CareDx Reports Strong Second Quarter 2026 Results with 52% Revenue Growth and Raises Full-Year Financial Outlook
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company focused on transplant medicine, specialty oncology, and cell therapy, has announced strong financial results for the second quarter ended June 30, 2026. The company delivered significant year-over-year growth across its core business segments while executing major strategic initiatives that strengthen its long-term position in molecular diagnostics.
During the quarter, CareDx generated record revenue, expanded profitability, completed the divestiture of its Lab Products business, finalized the acquisition of Naveris, and continued advancing its pipeline of innovative molecular diagnostic technologies. The company’s performance reflects growing adoption of its transplant testing portfolio, increased reimbursement support, and expanding clinical evidence supporting its precision medicine platform.
Revenue Climbs 52% as Core Testing Business Continues to Expand
CareDx reported total second-quarter revenue of $132 million, representing a 52% increase compared with $87 million during the same quarter in 2025.
The company’s growth was driven primarily by continued expansion of its Testing Services business, which remains the largest contributor to overall revenue. Additional growth came from Patient and Digital Solutions, while Lab Products also contributed prior to the completion of its divestiture at the end of June.
The strong performance demonstrates continued demand for molecular diagnostics among transplant centers, improved reimbursement dynamics, and broader adoption of CareDx’s precision testing solutions.
Testing Services Delivers Exceptional Growth
Testing Services generated $100 million in revenue during the quarter, representing a 61% increase year over year compared with $62 million in the second quarter of 2025.
Testing volume also increased significantly, reaching approximately 58,000 tests, an increase of 17% over the previous year.
The company reported an average revenue per test of approximately $1,720, which included approximately $16 million in revenue associated with testing performed during prior periods.
Excluding previously recognized revenue, Testing Services revenue still increased approximately 28% year over year, highlighting continued organic expansion across transplant monitoring programs.
Growth within this segment reflects increasing physician adoption of molecular surveillance testing for transplant recipients, both during routine patient monitoring and when evaluating potential complications or graft dysfunction.
Patient and Digital Solutions Continue Strong Momentum
CareDx’s Patient and Digital Solutions business also produced impressive growth during the quarter.
Revenue reached $19 million, representing a 50% increase compared with $13 million during the same period last year.
The company attributed this performance primarily to continued expansion of CareDx Pharmacy services alongside increasing utilization of digital patient engagement platforms and support services designed specifically for transplant recipients.
These offerings complement CareDx’s diagnostic testing by helping improve medication adherence, patient monitoring, and long-term transplant management.
Lab Products Business Contributes Prior to Divestiture
Lab Product revenue totaled $13 million, representing an 8% increase over the prior-year quarter.
Because the sale of the Lab Products business closed on June 30, 2026, the second quarter includes a full reporting period for this segment.
Future financial reports will no longer include Lab Products revenue following completion of the transaction with Eurobio Scientific.
The divestiture represents an important strategic decision as CareDx focuses resources on its higher-growth precision diagnostics businesses.
Strategic Portfolio Transformation
During the second quarter, CareDx completed two major strategic transactions that significantly reshape the company’s future direction.
First, the company finalized the sale of its Lab Products business to Eurobio Scientific, allowing greater focus on molecular diagnostics, transplant medicine, oncology, and cell therapy.
At the same time, CareDx completed the acquisition of Naveris, strengthening its capabilities in precision oncology diagnostics.
Together, these transactions further transform CareDx into a company centered on molecular testing and precision medicine rather than laboratory products.
Management believes this sharper strategic focus will support sustainable long-term growth while improving operational efficiency.
Significant Improvement in Profitability
CareDx reported a dramatic improvement in profitability during the second quarter.
GAAP net income reached $111 million, compared with a GAAP net loss of $9 million during the second quarter of 2025.
Basic GAAP earnings per share increased to $2.15, while diluted GAAP earnings per share totaled $2.07.
The substantial increase reflects both improved operational performance and the financial impact of the Lab Products divestiture.
The sale generated a $113 million gain, which is included within GAAP operating income but excluded from non-GAAP operating results.
Non-GAAP Results Show Strong Operational Progress
Excluding one-time items, CareDx also demonstrated meaningful operational improvement.
Non-GAAP net income increased to $20 million, compared with $6 million during the same quarter last year.
Diluted non-GAAP earnings per share improved to $0.37, compared with $0.10 in the second quarter of 2025.
The company also reported Adjusted EBITDA of $25 million, a substantial increase from $5 million one year earlier.
Management attributed this improvement to several factors, including:
- Strong Testing Services growth
- Higher gross profit margins
- Improved operating leverage
- Ongoing cost discipline
- Operational efficiency initiatives
Positive Operating Cash Flow
CareDx generated $31 million in cash flow from operations during the quarter.
The positive operating cash flow further strengthens the company’s financial position while providing flexibility to continue investing in product development, commercialization activities, and strategic acquisitions.
Medicare Coverage Supports Long-Term Growth
Beyond its financial performance, CareDx achieved several important regulatory and reimbursement milestones during the quarter.
One of the most significant developments was the finalization of Centers for Medicare & Medicaid Services (CMS) coverage policies supporting Medicare reimbursement for both AlloSure® and AlloMap®.
These molecular diagnostic tests play important roles in transplant patient management by helping clinicians monitor organ health and identify potential rejection.
Expanded Medicare coverage helps ensure continued patient access while supporting broader adoption across transplant programs nationwide.
Pipeline Programs Continue Advancing
CareDx also reported meaningful progress across several pipeline programs.
The company advanced development of AlloHeme®, submitting a clinical validation manuscript while continuing preparations for CLIA laboratory readiness.
AlloHeme represents an important expansion of CareDx’s molecular diagnostics portfolio into cell therapy applications.
Meanwhile, new HistoMap® Kidney data published in the journal Transplantation expanded the scientific evidence supporting molecular assessment as a complement to traditional kidney biopsy evaluation.
The findings suggest molecular diagnostics may provide additional insights beyond conventional histopathology for kidney transplant monitoring.
Expanding Evidence for NavDx
CareDx also strengthened the clinical evidence supporting NavDx®, its molecular diagnostic platform for oncology applications.
New clinical findings were presented during the American Head and Neck Society (AHNS) Annual Meeting, demonstrating the test’s role in supporting patient management decisions.
The acquisition of Naveris further enhances CareDx’s capabilities in oncology diagnostics and broadens opportunities beyond transplantation.
Additional Clinical Evidence for AlloSure
The company also presented multiple new studies supporting AlloSure® during the American Transplant Congress (ATC).
The research demonstrated the test’s value in:
- Identifying transplant recipients at increased risk of graft loss
- Monitoring patient response to therapy
- Supporting earlier clinical intervention
- Enhancing long-term transplant surveillance
In addition, newly published KOAR study findings in the Journal of the American Society of Nephrology further supported the use of AlloSure Kidney for longitudinal risk stratification and clinical decision-making among kidney transplant recipients.
Together, these studies continue strengthening the scientific foundation supporting CareDx’s testing portfolio.
Leadership Highlights Strategic Progress
President and Chief Executive Officer John Hanna emphasized that the company’s recent transformation is producing measurable results.
According to Hanna, CareDx has evolved into a differentiated precision molecular diagnostics organization possessing unique scientific capabilities that position it for continued profitable growth.
He noted that the company’s financial performance validates its strategic direction while expressing confidence that integrating Naveris and expanding into cell therapy diagnostics will create additional opportunities in the future.
Raising Full-Year 2026 Financial Guidance
Reflecting its strong first-half performance and continued business momentum, CareDx increased its financial outlook for the remainder of 2026.
The company now expects full-year revenue between $490 million and $500 million, significantly higher than its previous guidance range of $447 million to $465 million.
CareDx also raised its Adjusted EBITDA expectations.
The company now projects Adjusted EBITDA between $66 million and $78 million, compared with its earlier guidance of $43 million to $57 million.
The revised outlook reflects confidence in continued testing volume growth, reimbursement stability, expanding transplant adoption, operational efficiencies, and ongoing commercial execution.
Positioned for Continued Growth
CareDx enters the second half of 2026 with strong financial momentum, an increasingly focused business model, expanding clinical evidence, and a growing precision diagnostics portfolio.
The successful completion of major strategic transactions, combined with accelerating adoption of molecular transplant testing, strengthened Medicare coverage, and expanding oncology capabilities, positions the company for continued growth across transplant medicine, specialty oncology, and emerging cell therapy applications.
With improved profitability, stronger cash generation, and raised financial guidance, CareDx appears well positioned to continue executing its long-term strategy of becoming a leading precision medicine diagnostics company serving clinicians and patients across multiple areas of advanced healthcare.
About CareDx
CareDx is a leading precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, CareDx is dedicated to improving patient outcomes. For more information, please visit www.caredx.com.